Press releasePRNewswire
Boundless Bio
BOLD · NASDAQ
$2.43+$0.12 (+5.19%)TodayMarket closed ·
Prev close $2.31
Latest news
- Press releaseGlobe Newswire
Serapha Bio Appoints Kenneth T. Mills as Chief Executive Officer and Names Senior Leadership Team to Advance Potential Best-in-Class in vivo Base Editing Program for Alpha-1 Antitrypsin Deficiency
- Press releasePRNewswire
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?
- Press releasePRNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Crude Oil Down Over 1%; US Manufacturing PMI Surges In June
- Press releaseBusiness Wire
BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders
- Press releaseGlobe Newswire
These Emerging Companies Are Racing Toward Major Catalysts
- NewsAvi Kapoor
Dow Falls Over 300 Points; Korn Ferry Earnings Top Views
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releaseGlobe Newswire
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
- Press releaseGlobe Newswire
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
- Press releaseGlobe Newswire
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
- Press releaseGlobe Newswire
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
- Press releaseGlobe Newswire
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
- Press releasePRNewswire
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- Press releaseGlobe Newswire
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
- Press releaseGlobe Newswire
Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights
- Press releasePRNewswire
Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.